FGP
BLFS icon

Freestone Grove Partners’s BioLife Solutions BLFS Stock Holding History

Freestone Grove Partners’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,163
Closed -$98.5K – 1045
2026
Q1 		$98.5K Buy
+5,163
New +$114K ﹤0.01% 806

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Freestone Grove Partners's BLFS Position: Q2 2026 in Review

Freestone Grove Partners sold out of BioLife Solutions (BLFS) in Q2 2026, closing a stake of 5,163 shares — an estimated $98.5K sold.

Freestone Grove Partners first reported a position in BLFS in Q1 2026 and held it in 1 quarter. The position peaked at $98.5K in Q1 2026. 217 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

  • Freestone Grove Partners reported no remaining BioLife Solutions position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 5,163 BioLife Solutions shares in Q2 2026, an estimated $98.5K.
  • Freestone Grove Partners first reported a position in BioLife Solutions in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's BioLife Solutions position peaked at $98.5K in Q1 2026.
  • 217 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.